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ABSTRACT
Background. Combination of the University of Califor-
nia, San Francisco (UCSF) and the up-to-7 criteria with
alpha-fetoprotein (AFP) cutoff of 100 ng/ml was proposed
as the Warsaw expansion of the Milan criteria in selection
of hepatocellular cancer (HCC) patients for liver trans-
plantation. The purpose of this retrospective study was to
validate this proposal.
Methods. A total of 240 HCC patients after liver trans-
plantation were included. Recurrence-free survival and
overall survival at 5 years were set as the primary and
secondary outcome measures, respectively.
Results. The Warsaw expansion increased transplant eli-
gibility rate by 20.3 %. AFP[100 ng/ml significantly
increased the recurrence risk in patients within the Milan
criteria (p = 0.025) and in those beyond, yet within either
the UCSF or the up-to-7 criteria (p\ 0.001). Recurrence-
free survival at 5 years was 90.8 % for patients within the
Milan criteria, 100.0 % in patients within the Warsaw
expansion, 54.9 % in patients beyond the Warsaw expansion
but within either the UCSF or the up-to-7 criteria, and 45.1 %
in patients beyond both the UCSF and the up-to-7 criteria
(p\ 0.001). The corresponding overall survival rates were
71.6, 82.4, 64.3, and 55.3 %, respectively (p = 0.027).
Conclusions. The Warsaw expansion of the Milan criteria
substantially increases the recipient pool without compro-
mising outcomes.
Liver transplantation is the optimal treatment for
selected patients with hepatocellular cancer (HCC) and
liver cirrhosis.1,2 Despite available evidence for the supe-
riority of long-term outcomes of patients undergoing liver
transplantation as a first-line management over those
undergoing liver resection or salvage liver transplantation,
its use remains limited by the worldwide shortage of
donors.3–8 Accordingly, the restrictive Milan criteria (1
tumor \5 cm or 2–3 tumors \3 cm each combined with
the absence of extrahepatic lesions or macrovascular
invasion) introduced two decades ago are still the gold
standard in selecting patients eligible for transplantation,
despite the increasing number of reports on the noninferi-
ority of their modest expansion.9–13 Of numerous
morphology-based expansion proposals, the University of
California, San Francisco criteria (1 tumor\6.5 cm or 2–3
tumors\4.5 cm with total tumor diameter\8 cm) and the
up-to-7 criteria (sum of number of tumors and size of the
largest tumor in cm not exceeding 7) appear most popular
and widely evaluated.14,15 However, the risk of posttrans-
plant recurrence is dependent upon morphological tumor
burden and long-term survival of patients undergoing liver
transplantation for HCC is inferior to those with benign
indications even with the widespread use of Milan crite-
ria.16–18 Therefore, expansion of limits for tumor size and
number is subject to criticism.19–21
Considering the increasing evidence for the independent
role of serum tumor markers, particularly alpha-fetoprotein
(AFP), in prediction of posttransplant tumor recurrence,
modification of the morphology-based criteria using these
markers of biological aggressiveness seems not only jus-
tified, but also necessary.22–25 Notably, while serum tumor
markers already have been included in several criteria
proposals utilized in Asian countries, utilization of such
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strategy is uncommon in European and American coun-
tries, besides a recent French AFP model by Duvoux et al.
and the AFP total tumor volume (TTV) criteria by Toso
et al.26–32 In view of geographical discrepancies in the
selection criteria and following a detailed set of analyses of
the associations between pretransplant AFP and the risk of
posttransplant tumor recurrence, AFP was included in the
Warsaw proposal for safe extension of Milan criteria.
Briefly, it defines patient eligibility either (1) by fulfillment
of the Milan criteria, irrespective of pretransplant AFP, or
(2) fulfillment of the up-to-7 or UCSF criteria and AFP
\100 ng/ml.33 In the initial study, the latter subgroup was
characterized by the ideal 5-year, recurrence-free survival
of 100 %. This proposal was started to be taken under
consideration during selection of HCC patients for liver
transplantation since the beginning of 2013. Therefore, the
purpose of the present study was to evaluate the efficacy of
the Warsaw proposal for selection of HCC patients for liver
transplantation in provision of acceptable low-risk of post-
transplant recurrence.
METHODS
A total of 1602 liver transplantations were performed in
the Department of General, Transplant and Liver Surgery
at the Medical University of Warsaw (Poland) during the
period between December 1989 and April 2015. This ret-
rospective cohort study was performed using the data of
240 patients after liver transplantation for HCC between
January 2001 and April 2015. The study protocol was
approved by the local ethics committee of the Medical
University of Warsaw.
Tumor recurrence at 5-year, follow-up period was set as a
primary endpoint of the study, with 5-year recurrence free
survival (RFS) being the primary outcome measure. The
5-year RFS was calculated as the time from liver trans-
plantation until diagnosis of recurrence and was censored at
the date of last follow-up or death from a nonmalignant
cause. The secondary endpoint was patient death at 5 years
(irrespective of the cause), which was used to calculate
overall survival (OS, secondary outcome measure). Details
on the center’s experience, perioperative management,
operative technique, immunosuppression protocol, and
long-term follow-up were provided elsewhere.34,35
Primary and secondary outcome measures were evalu-
ated separately in patients (1) within the Milan criteria, (2)
beyond the Milan criteria but within the up-to-7 or the
UCSF criteria with AFP\100 ng/ml (Warsaw proposal for
extension of the Milan criteria), (3)[100 ng/ml, and (4) in
patients beyond both the UCSF and the up-to-7 criteria.
The particular selection criteria and last pretransplant AFP,
as primary variables of interest, were assessed as risk
factors for tumor recurrence at 5 years. This was done both
in a series of univariable analyses and in multivariable
analyses, following adjustment for the impact of other risk
factors for rumor recurrence.
Quantitative variables were presented as medians (in-
terquartile ranges) and qualitative variables were presented
as numbers (percentages). Kruskal–Wallis test and Chi-
square test were used for intergroup comparisons, as
appropriate. Kaplan-Meier estimator was used to calculate
survival curves and log-rank test was used for the corre-
sponding comparisons. Reverse Kaplan–Meier method was
used to calculate median follow-up. Cox proportional
hazards regression models were used to evaluate the risk
factors for tumor recurrence. Due to the number of events,
a series of three variable models were used instead of a one
multivariable model. Hazard ratios (HRs) were presented
with 95 % confidence intervals (95% CI). The level of
statistical significance was set to 0.05. STATISTICA ver-
sion 12 software (StatSoft Inc., Tulsa, OK) was applied for
computing statistical analyses.
RESULTS
Of 240 patients included in the study, 143 (59.6 %) were
within the Milan criteria, 171 (71.3 %) were within the
UCSF criteria, and 181 (75.4 %) were within the up-to-7
criteria. Compared with the fulfillment of Milan criteria,
utilization of Warsaw extension results in 20.3 % increase in
the number of potential HCC recipients (143–172). Com-
parisons of baseline characteristics between patients within
the Milan criteria, beyond the Milan criteria but within the
UCSF or the up-to-7 criteria with AFP\100 ng/ml (Warsaw
extension), and beyond that limits are presented in Table 1.
Besides fulfillment of the particular selection criteria, sig-
nificant differences between these subgroups were found
with respect to AFP concentration (p\ 0.001), number of
tumors (p\ 0.001), size of the largest tumor (p\ 0.001),
total tumor volume (p\ 0.001), microvascular invasion
(p\ 0.001), tumor differentiation (p = 0.037), and neoad-
juvant treatment (p = 0.040). Median follow-up was 34
months. In the entire study cohort, 31 patients developed
tumor recurrence within 5 years posttransplantation with the
RFS rates of 92.3 % at 1 year, 84.8 % at 3 years, and 79.5 %
at 5 years. There were 49 deaths in the 5-year posttransplant
period with the corresponding OS rates of 89.0, 79.8, and
68.8 %, respectively.
According to the results of univariable analyses, the
Milan criteria (p\ 0.001), the UCSF criteria (p\ 0.001),
the up-to-7 criteria (p\ 0.001), and the last pretransplant
AFP (p\ 0.001) were significantly associated with the risk
of posttransplant tumor recurrence (Table 2). Other risk
factors comprised younger recipient age (p = 0.034),
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presence of microvascular invasion (p = 0.029), poor tumor
differentiation (p = 0.013), and morphological tumor fea-
tures: number of tumors (p\ 0.001), size of the largest
tumor (p = 0.001), and total tumor volume (p\ 0.001).
Notably, AFP[100 ng/ml was a significant risk factor for
tumor recurrence in patients within the Milan criteria (HR
7.00; 95 % CI 1.28–38.3; p = 0.025) and in those beyond
the Milan criteria but within either the UCSF or the up-to-7
criteria (100.0 vs. 54.9 %, p\ 0.001), however not in
patients beyond both the UCSF and the up-to-7 criteria
(HR 1.73; 95 % CI 0.70–4.29; p = 0.236). Furthermore, a
series of multivariable (3-factor) analyses revealed that
nonfulfillment of each of the analyzed criteria and AFP
[100 ng/ml were independent risk factors for worse 5-year
RFS (Table 3). As each of the three particular selection
criteria are solely defined by morphological tumor features,
number of tumors, size of the largest tumor and total tumor
volume were not included in the multivariable models.
Patients within the Milan criteria exhibited a 5-year RFS
rate of 90.8 %, significantly higher than that observed for
patients beyond the Milan criteria (64.2 %, p\ 0.001;
Fig. 1a). The OS rates in the corresponding subgroups were
71.6% and 65.4%, respectively (p = 0.055; Fig. 1b).
Compared with patients within the Milan criteria, patients
beyond Milan but within either the UCSF or the up-to-7
criteria exhibited nonsignificantly lower 5-year RFS of
88.0 % (p = 0.350), yet higher than that observed for
patients beyond the UCSF and the up-to-7 criteria (45.1 %,
p = 0.004; Fig. 1c). The only significant difference
between these subgroups with respect to OS was found
between patients within the Milan criteria and those
beyond the up-to-7 and the UCSF criteria (71.6 vs. 55.3 %,
p = 0.012; Fig. 1d). Notably, RFS at 5 years for patients
beyond the Milan criteria but within their Warsaw exten-
sion was 100 % compared with 90.8 % in patients within
the Milan criteria (p = 0.161), 54.9 % in patients beyond
TABLE 1 Comparison of baseline characteristics between patients within the Milan criteria, patients beyond Milan criteria but within the UCSF
or up-to-7 criteria with AFP\100 ng/ml (the Warsaw extension), and patients beyond the Warsaw extension








Male 100 (69.9 %) 19 (65.5 %) 54 (79.4 %)
Female 43 (30.1 %) 10 (34.5 %) 14 (20.6 %)
Recipient age (yr) 57 (52–61) 58 (53–61) 56 (52–61) 0.573
MELD 11 (9–13) 9 (7–12) 11 (8–14) 0.183
HCV infection 100 (69.9 %) 20 (69.0 %) 49 (72.1 %) 0.935
HBV infection 64 (44.8 %) 12 (41.4 %) 26 (38.2 %) 0.664
Within UCSF criteria 143 (100.0 %) 19 (65.5 %) 9 (13.2%) \0.001
Within up-to-7 criteria 143 (100.0 %) 27 (93.1 %) 11 (16.2 %) \0.001
Number of tumors 1 (1–2) 2 (1–3) 4 (2–7) \0.001
Size of the largest tumor (mm) 25 (15–33) 40 (33–51) 45 (35–60) \0.001
Total tumor volume (cm3) 8 (2–22) 44 (28–80) 88 (49–131) \0.001
Pretransplant AFP (ng/ml) 13 (5–58) 11 (6–21) 114 (14–914) \0.001
Pretransplant AFP
\0.001
[100 ng/ml 28 (20.4 %) 0 (0.0 %) 34 (50.7 %)
\100 ng/ml 109 (79.6 %) 29 (100.0 %) 33 (49.3 %)
Poor tumor differentiation 9 (6.3 %) 3 (10.3 %) 12 (17.6 %) 0.037
Microvascular invasion 22 (15.5 %) 11 (39.3 %) 34 (52.3 %) \0.001
Neoadjuvant treatment 57 (39.9 %) 19 (65.5 %) 30 (44.1 %) 0.040
Total ischemic time (hr) 9.0 (8.0–10.4) 9.8 (8.5–10.5) 9.3 (8.0–10.3) 0.553
Intraoperative PRBC transfusions
(units)
3 (0–6) 3 (2–5) 4 (2–6) 0.420
Intraoperative FFP transfusions (units) 6 (4–10) 7 (5–10) 7 (5–10) 0.232
Data are presented as medians (interquartile ranges) or numbers (percentages)
UCSF University of California, San Francisco; AFP alpha-fetoprotein; MELD model for end-stage liver disease; HCV hepatitis C virus; HBV
hepatitis B virus; PRBC packed red blood cells; FFP fresh frozen plasma
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the Milan criteria but within either the UCSF or the up-to-7
criteria and AFP [100 ng/ml (p\ 0.001), and 45.1 % in
patients beyond the UCSF and the up-to-7 criteria
(p\ 0.001; Fig. 2a). At 5 years, OS was significantly
better for both patients within the Milan criteria (71.6 %)
and those beyond the Milan criteria but within their War-
saw extension (82.4 %) compared with patients beyond the
UCSF and the up-to-7 criteria (55.3 %, p = 0.012, 0.045,
TABLE 2 Results of univariable analyses of risk factors for 5-year tumor recurrence
Factors Hazard ratio 95 % confidence interval P
Male recipient gender 0.84 0.39–1.83 0.663
Recipient age 0.97 0.93–0.99 0.034
MELD 0.99 0.92–1.07 0.814
HCV infection 1.00 0.47–2.13 0.998
HBV infection 1.41 0.69–2.85 0.343
Within Milan criteria 0.22 0.10–0.48 \0.001
Within UCSF criteria 0.25 0.12–0.50 \0.001
Within up-to-7 criteria 0.17 0.08–0.36 \0.001
Number of tumors 1.31 1.18–1.44 \0.001
Size of the largest tumor 1.02 1.01–1.04 0.001
Total tumor volume 1.01 1.01–1.02 \0.001
Pre-transplant AFP[100 ng/ml 4.30 2.05–9.00 \0.001
Poor tumor differentiation 2.90 1.25–6.73 0.013
Microvascular invasion 2.23 1.09–4.57 0.029
Neoadjuvant treatment 1.36 0.67–2.76 0.393
Total ischemic time 1.15 0.94–1.39 0.172
Intraoperative PRBC transfusions 1.00 0.93–1.07 0.986
Intraoperative FFP transfusions 0.98 0.90–1.06 0.626
Hazard ratios were given per: 1 year increase for recipient age; 1 point increase for model for end-stage liver disease; 1 tumor more for number
of tumors; 1 mm increase for the size of the largest tumor; 10 cm3 increase for total tumor volume; 1 loge increase for alpha-fetoprotein; 1 h
increase for total ischemic time; and 1 unit increase for packed red blood cells and fresh frozen plasma transfusions
MELD model for end-stage liver disease; HCV hepatitis C virus; HBV hepatitis B virus; UCSF University of California, San Francisco; AFP
alpha-fetoprotein; PRBC packed red blood cells; FFP fresh frozen plasma
TABLE 3 Multivariable (3-factor) analyses of the associations between fulfillment of particular selection criteria and AFP over 100 ng/ml and
the risk of posttransplant tumor recurrence
Factors The effects of selection criteria fulfillment and AFP on recurrence-free survival adjusted for
Microvascular invasion Poor tumor differentiation Recipient age
HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P
Milan criteria and AFP
Within Milan criteria 0.20 (0.08–0.50) \0.001 0.19 (0.08–0.48) \0.001 0.18 (0.07–0.44) \0.001
AFP[100 ng/ml 3.98 (1.87–8.47) \0.001 3.56 (1.69–7.52) \0.001 3.46 (1.62–7.41) 0.001
UCSF criteria and AFP
Within UCSF criteria 0.26 (0.12–0.57) \0.001 0.25 (0.11–0.54) \0.001 0.23 (0.10–0.50) \.001
AFP[100 ng/ml 3.83 (1.81–8.12) \0.001 3.31 (1.55–7.08) 0.002 3.38 (1.58–7.22) .002
Up-to-7 criteria and AFP
Within up-to-7 criteria 0.19 (0.08–0.42) \0.001 0.17 (0.08–0.37) \0.001 0.18 (0.08–0.38) \.001
AFP[100 ng/ml 3.60 (1.69–7.64) \0.001 3.18 (1.50–6.75) 0.003 3.27 (1.53–6.99) .002
AFP alpha-fetoprotein; HR hazard ratio; 95 % CI 95 % confidence interval; UCSF University of California, San Francisco
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respectively; Fig. 2b). Finally, patients within the Warsaw
extended criteria exhibited 5-year RFS and OS rates of 92.5
and 73.5%, respectively, compared with the corresponding
rates of 47.9 % (p\ 0.001) and 57.4 % (p = 0.004),
respectively, in patients beyond these criteria (Fig. 2c, d).
DISCUSSION
To keep the rates of tumor recurrence after liver trans-
plantation for HCC within the acceptable limits and long-
term posttransplant survival of HCC patients comparable to
recipients with nonmalignant diseases, the Milan criteria
remained the benchmark for assessing patient eligibility for
transplantation for the past two decades. The results of
previous study from the authors’ department provided the
rationale for expansion of these criteria based on the
combination of two well-known morphological expansions,
namely the UCSF and the up-to-7 criteria, and the bio-
logical criterion of AFP\100 ng/ml.33 The results of the
present study provide further evidence on the lack of any
negative effects associated with expansion of the Milan
criteria into the Warsaw expanded criteria.
The major disadvantage of the proposals for expansion
of Milan criteria based only on morphological features is
the potential risk of concomitant increase in the risk of
posttransplant tumor recurrence. Despite the optimistic
results of prospective validation of the UCSF criteria and
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FIG. 1 Recurrence-free survival and overall survival curves in
patients within (solid lines) and beyond (dashed lines) the Milan
criteria (a, b) and in patients within the Milan criteria (solid lines),
beyond the Milan but within either the UCSF or the up-to-7 criteria
(dashed lines), and beyond (dotted lines) both the UCSF and the up-
to-7 criteria (c, d). Numbers of patients at risk are presented below the
particular graphs
530 M. Gra˛t et al.
acceptable posttransplant outcomes in patients within
either of the two expanded criteria, increase in tumor
number and size is a well-known factor associated with the
recurrence risk.15,36–40 In fact, the significant effects of
tumor number and size have been the basis for creation of
the Metroticket model.15 Accordingly, patients beyond
Milan but within the limits of the UCSF criteria were
previously reported to exhibit inferior long-term out-
comes.41,42 In the present study, all morphological tumor
characteristics were found to be significantly associated
with the risk of posttransplant recurrence. Although the
long-term outcomes were not significantly compromised in
patients beyond Milan but within either the UCSF or the
up-to-7 criteria, this might have been affected by the type II
error or, less probably, by the selection bias.
Performed analyses revealed that last pretransplant
AFP was an independent risk factor for tumor recur-
rence; however, the effects varied with respect to
fulfillment of different selection criteria. Notably, while
the negative impact of AFP [100 ng/ml was statistically
and clinically significant in patients within the Milan
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FIG. 2 Recurrence-free survival and overall survival curves in
patients within the Milan criteria (solid lines), beyond the Milan
criteria but within the Warsaw expansion (short-dashed lines),
beyond the Milan criteria and Warsaw expansion but within either
the UCSF or the up-to-7 criteria (dotted lines), and beyond both the
UCSF and the up-to-7 criteria (long-dashed lines) (a, b) and in
patients within (solid lines) and beyond (dashed lines) the Warsaw
criteria (c, d). Numbers of patients at risk are presented below the
particular graphs
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criteria, no effects were observed in patients beyond the
extended criteria. These results clearly support addition
of biological criterion of AFP into the morphological
criteria. Most importantly, the null rate of recurrence
remained unchanged since the previous analysis, despite
both doubling the number of patients and prolongation of
the follow-up period for those included in the initial
study. Moreover, the findings are further supported by
incorporation of the Warsaw extended criteria in the
decision-making process regarding selection of patients
in the authors’ department since 2013, potentially
reducing the risk of selection bias.
Besides several selection criteria utilized in Asia, the
concept of combining the biological tumor markers with
morphological features is emerging in the Western per-
spective of liver transplantation for HCC. Important
alternatives to the Warsaw extended criteria currently
comprise the AFP model introduced by Duvoux et al. and
the TTV/AFP introduced by Toso et al.31,32 Subsequent
studies validated the AFP model with respect to both long-
term outcomes and net health benefit and the TTV/AFP
criteria with respect to long-term outcomes.43–46 In contrast
to these highly relevant proposals of complete redefinition
of the Milan criteria, the Warsaw proposal provides an
option to expand them in a more conservative fashion, by
using the well-established UCSF and up-to-7 criteria.
Therefore, AFP cutoff of 100 ng/ml is used in fact as an
exclusion criterion, to bring the risk of tumor recurrence
associated with increasing tumor burden to or below the
level provided by the Milan criteria. Presumably, the use of
the Warsaw extended criteria would expand the pool of
potential HCC recipients by approximately 20 %, similar
to the TTV/AFP criteria and the UCSF criteria, yet lower to
the up-to-7 criteria.47
Recently, the pretransplant AFP slope has been reported
to be a novel predictor of HCC recurrence after liver
transplantation.48 Nevertheless, this was not confirmed by
several other studies, including that of the authors of this
manuscript.49,50 However, the last pretransplant AFP also
provides a dynamic assessment of patients eligibility for
transplantation, as the AFP values are subject to sponta-
neous or neoadjuvant treatment-related changes in the
pretransplant period.
In conclusion, the results of the present study provide
further evidence for the potential lack of negative effects
associated with the use of the Warsaw expansion of Milan
criteria in selection of patients with HCC for liver
transplantation.
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